PBMs, FTC and IRA: Experts Tackle Pharma’s Tough Acronyms At BioFuture Conference

 
• By Jessica Merrill
  
A member of Congress said during the conference that he was sympathetic to industry efforts to change the time before drugs and biologics are subject to price negotiations. (Shutterstock)

More from PBMs

More from Elections